"To that end, we continue to make meaningful progress toward the execution of a definitive acquisition agreement under our previously announced letter of intent. Due diligence and negotiations of definitive transaction documents remain ongoing. Importantly, we have received and accepted financing and equity term sheets and are actively advancing the related due diligence, underwriting, and documentation processes. While these additional steps have extended the previously anticipated
"In previous years, the
Financial tables are below, and the Company's Quarterly Report on Form 10-Q is available on the
Conference Call
Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 937760. The call and the accompanying slide deck will also be webcast at:
https://www.webcaster5.com/Webcast/Page/3131/54813
An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until
-----
About
The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.
FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Use of Non-GAAP Financial Measures
Cardiff Lexington Investor Relations
investorrelations@cardifflexington.com
(800) 628-2100 ext. 705
or
IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200
CARDIFF
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED
(UNAUDITED)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Total revenue | $ | 1,912,179 | $ | 3,058,740 | $ | 6,294,016 | $ | 8,763,314 | ||||||||
Total cost of sales | 875,420 | 1,149,161 | 2,756,887 | 3,317,943 | ||||||||||||
Gross profit | 1,036,759 | 1,909,579 | 3,537,129 | 5,445,371 | ||||||||||||
Operating expenses | ||||||||||||||||
Depreciation expense | 233 | 762 | 1,079 | 4,890 | ||||||||||||
Loss on disposal of fixed assets | 0 | 0 | 0 | 12,593 | ||||||||||||
Stock compensation expense | 369,981 | 41,188 | 1,401,116 | 138,688 | ||||||||||||
Selling, general and administrative | 1,203,211 | 1,224,350 | 3,727,402 | 3,492,310 | ||||||||||||
Total operating expenses | 1,573,425 | 1,266,300 | 5,129,597 | 3,648,481 | ||||||||||||
(Loss) income from operations | (536,666 | ) | 643,279 | (1,592,468 | ) | 1,796,890 | ||||||||||
Other (expense) income : | ||||||||||||||||
Other income (expense) | (106,593 | ) | (20,550 | ) | (96,512 | ) | (22,147 | ) | ||||||||
Loss on settlement of debt | (16,498 | ) | 0 | (16,498 | ) | 0 | ||||||||||
Penalties and fees | (5,500 | ) | (1,500 | ) | (5,500 | ) | (1,500 | ) | ||||||||
Derivative liability loss on issuance and change in fair value | (50,242 | ) | 0 | (493,014 | ) | 0 | ||||||||||
Interest expense | (2,468,536 | ) | (1,765,528 | ) | (6,516,692 | ) | (4,594,714 | ) | ||||||||
Amortization of debt discounts | (22,516 | ) | 0 | (56,847 | ) | 0 | ||||||||||
Total other expense | (2,669,885 | ) | (1,787,578 | ) | (7,185,063 | ) | (4,618,361 | ) | ||||||||
Net loss | $ | (3,206,551 | ) | $ | (1,144,299 | ) | $ | (8,777,531 | ) | $ | (2,821,471 | ) | ||||
*Shares outstanding for the three and nine months ended
CARDIFF
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF
| 2026 | 2025 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 584,319 | $ | 318,535 | ||||
Accounts receivable, net | 23,400,209 | 22,070,954 | ||||||
Prepaid and other current assets | 234,768 | 203,876 | ||||||
Total current assets | 24,219,296 | 22,593,365 | ||||||
Property and equipment, net | 1,874 | 2,953 | ||||||
Land | 540,000 | 540,000 | ||||||
| 5,666,608 | 5,666,608 | |||||||
Right of use - assets | 75,266 | 214,858 | ||||||
Due from related party | 4,979 | 4,979 | ||||||
Other assets | 74,789 | 64,182 | ||||||
Total assets | $ | 30,582,812 | $ | 29,086,945 | ||||
LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' DEFICIT | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued expense | $ | 1,707,311 | $ | 1,760,765 | ||||
Accrued expenses - related parties | 568,048 | 4,645,826 | ||||||
Accrued interest | 834,801 | 707,574 | ||||||
Right of use - operating lease liability | 75,728 | 178,524 | ||||||
Notes payable - current portion | 15,689 | 125,774 | ||||||
Notes payable related parties - current portion | 1,085,703 | 1,085,703 | ||||||
Line of credit | 23,439,491 | 17,209,908 | ||||||
Convertible notes payable, net of debt discounts of respectively | 240,205 | 118,295 | ||||||
Derivative liability | 539,130 | 0 | ||||||
Total current liabilities | 28,506,106 | 25,832,369 | ||||||
Other liabilities | ||||||||
Operating lease liability - long term | 0 | 42,976 | ||||||
Notes payable | 136,289 | 138,773 | ||||||
Notes payable related parties | 350,000 | 0 | ||||||
Total liabilities | 28,992,395 | 26,014,118 | ||||||
Mezzanine equity | ||||||||
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, and outstanding at | 0 | 3,802,010 | ||||||
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, issued and outstanding at respectively | 1,873,929 | 1,740,478 | ||||||
Total Mezzanine Equity | 1,873,929 | 5,542,488 | ||||||
Stockholders' deficit | ||||||||
Series A-1 Preferred Stock - 2 shares authorized, 2025 | 500 | 0 | ||||||
Series F-1 Preferred Stock - 50,000 shares authorized, value | 15,500 | 15,500 | ||||||
Series L Preferred Stock - 400,000 shares authorized, value | 1,277,972 | 1,277,972 | ||||||
Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, par value, stated value | 4,185,670 | 0 | ||||||
Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, par value, stated value of outstanding at | 4,602,107 | 4,271,512 | ||||||
Common Stock; 300,000,000 shares authorized, 13,701,698 shares issued and outstanding at 31, 2025, respectively | 17,026 | 13,702 | ||||||
Additional paid-in capital | 78,860,451 | 72,021,848 | ||||||
Unearned stock compensation | (125,065 | ) | (579,215 | ) | ||||
Accumulated deficit | (89,117,673 | ) | (79,490,980 | ) | ||||
Total stockholders' deficit | (283,512 | ) | (2,469,661 | ) | ||||
Total liabilities, mezzanine equity and stockholders' deficit | $ | 30,582,312 | $ | 29,086,945 | ||||
CARDIFF
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED
(Unaudited)
The following table reconciles Net income (loss) before discontinued operations (a GAAP financial measure) to EBITDA and Adjusted EBITDA (non-GAAP financial measures)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
EBITDA (1) | ||||||||||||||||
Net loss before discontinued operations | $ | (3,206,551 | ) | $ | (1,144,299 | ) | $ | (8,777,531 | ) | $ | (2,821,471 | ) | ||||
Add: | ||||||||||||||||
Interest | 2,468,536 | 1,765,528 | 6,516,692 | 4,594,714 | ||||||||||||
Taxes | 0 | 0 | 0 | 0 | ||||||||||||
Depreciation | 233 | 762 | 1,079 | 4,890 | ||||||||||||
Amortization | 22,516 | 0 | 56,847 | 0 | ||||||||||||
EBITDA (1) | $ | (715,266 | ) | $ | 621,991 | $ | (2,202,913 | ) | $ | 1,778,133 | ||||||
Adjusted EBITDA (2) | ||||||||||||||||
EBITDA | $ | (715,266 | ) | $ | 621,991 | $ | (2,202,913 | ) | $ | 1,778,133 | ||||||
Add: | ||||||||||||||||
Derivative liability loss on issuance and change in fair value | 50,242 | 0 | 493,014 | 0 | ||||||||||||
Loss on settlement of debt | 16,498 | 0 | 16,498 | 0 | ||||||||||||
Stock compensation expense for shares issued | 369,981 | 41,188 | 1,401,116 | 138,688 | ||||||||||||
Adjusted EBITDA (2) | $ | (278,545 | ) | $ | 663,179 | $ | (292,285 | ) | $ | 1,916,821 | ||||||
| (1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization. | ||||||||||||||||
| (2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges. | ||||||||||||||||
Adjusted EBITDA excluding other non-recurring costs (3) | ||||||||||||||||
Adjusted EBITDA | $ | (278,545 | ) | $ | 663,179 | $ | (292,285 | ) | $ | 1,916,821 | ||||||
Add: | ||||||||||||||||
Scaling and restructuring business growth costs | 12,708 | 0 | 82,185 | 11,676 | ||||||||||||
Offering costs | 106,593 | 0 | 106,593 | 0 | ||||||||||||
Acquisition costs | 56,558 | 113,436 | 274,362 | 171,515 | ||||||||||||
Adjusted EBITDA excluding other non-recurring costs (3) | $ | (102,686 | ) | $ | 776,615 | $ | 170,855 | $ | 2,100,012 | |||||||
| (3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs. | ||||||||||||||||
SOURCE:
View the original press release on ACCESS Newswire